Is Chemours (CC) Undervalued Or Are Legal Risks Already Priced In?

Chemours (CC) has drawn fresh attention after recent trading, with the stock closing at $16.61 on 29 July 2026. Investors are weighing this move against the company’s mixed return profile and current valuation metrics.

See our latest analysis for Chemours.

Chemours’ recent pullback, including a 1 day share price return of down 2.92% and a 30 day share price return of down 17.53%, sits against a stronger year to date share price return of 35.59% and a 1 year total shareholder return of 47.58%. This suggests short term momentum has faded even as longer term holders have still seen gains.

If Chemours’ recent volatility has you thinking about portfolio balance, this could be a good moment to broaden your watchlist with 8 top copper producer stocks

Bulls see Chemours’ recent slide as an entry into a discounted asset, while bears point to the company’s loss making bottom line and weak multi year returns. Which case fits the current valuation evidence better?

Most Popular Narrative: 33% Undervalued

The most followed Chemours narrative pegs fair value at $24.67, which sits well above the latest close at $16.61. That gap rests on a detailed earnings and margin recovery story.

Acceleration in regulatory-driven adoption of low global warming potential (GWP) refrigerants is boosting sustained demand for Chemours' Opteon franchise, recent strong net sales and high margins signal that continued market share gains and capacity expansions will drive robust revenue and EBITDA growth through and beyond the 2025 and 2026 transition periods.

Read the complete narrative.

Want to see how Chemours gets from current losses to a higher fair value? The core of this narrative is a sharp profit swing, built on steady top line growth and a future earnings multiple that sits well below many peers. Curious which margin assumptions and revenue path make that price tag add up.

Result: Fair Value of $24.67 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Chemours narrative still faces real pressure from unresolved PFAS litigation costs and from potential margin strain if TiO2 pricing or end market demand weakens further.

Find out about the key risks to this Chemours narrative.

Next Steps

With Chemours facing both legal risks and a potential upside narrative, this is a moment to move quickly and test the story against the numbers yourself using 4 key rewards and 2 important warning signs

Looking for more Chemours investment ideas beyond this stock?

If Chemours has sharpened your focus on finding stronger opportunities, do not stop here. Use the Simply Wall Street screener to spot ideas you might otherwise miss.

• Target potential mispricings by scanning a focused set of companies that screen as 55 high quality undervalued stocks.
• Strengthen your income stream by zeroing in on companies that show up as 9 dividend fortresses.
• Reduce portfolio risk by filtering for businesses highlighted in the 81 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com